Target Name: MICU3
NCBI ID: G286097
Other Name(s): EF hand domain family, member A2 | EF-hand domain family member A2 | Calcium uptake protein 3, mitochondrial (isoform 1) | DKFZp313A0139 | MICU3 variant 1 | Mitochondrial calcium uptake family member 3, transcript variant 1 | EF hand domain family A2 | mitochondrial uptake family, member 3 | EF-hand domain-containing family member A2 | EF-hand domain family, member A2 | Calcium uptake protein 3, mitochondrial | MICU3_HUMAN | mitochondrial calcium uptake family member 3 | EFHA2

MICU3: A Potential Drug Target for Neurological Disorders

MICU3, also known as EF hand domain family member A2, is a protein that is expressed in brain and spinal cord tissue and is involved in the development and maintenance of neural circuits. It is a protein that has been identified as a potential drug target for a variety of neurological and psychiatric disorders, including Alzheimer's disease, Parkinson's disease, and schizophrenia.

MICU3 is a member of the EF hand domain family, which is a group of proteins that are characterized by the presence of a specific domain called the EF hand. This domain is responsible for the protein's unique structure and function, as well as its ability to interact with other proteins. The EF hand domain is found in a variety of organisms, including humans, and is thought to be involved in the regulation of a wide range of cellular processes, including cell signaling, protein-protein interactions, and intracellular signaling.

One of the unique features of MICU3 is its expression pattern in brain and spinal cord tissue. MICU3 is primarily expressed in the cerebral cortical cortical layer, which is the outer layer of the brain and is responsible for various higher-order cognitive functions. It is also found in the spinal cord and is thought to play a role in the development and maintenance of neural circuits in the central nervous system.

MICU3's involvement in neural circuit development and maintenance makes it a potentially interesting drug target for a variety of neurological and psychiatric disorders. For example, MICU3 has been shown to be involved in the regulation of synaptic plasticity, which is the ability of the brain to change and adapt in response to experience. Studies have shown that MICU3 is involved in the formation of synaptic plasticity in the brain, and that alterations in its expression or function can have a negative impact on synaptic plasticity.

MICU3 has also been shown to be involved in the regulation of neurotransmitter release, which is the process by which nerve impulses are transmitted from the brain to the rest of the body. Studies have shown that MICU3 is involved in the regulation of the release of dopamine , a neurotransmitter that is involved in mood, emotion, and motivation.

MICU3's involvement in the regulation of synaptic plasticity and neurotransmitter release makes it a potentially interesting drug target for a variety of neurological and psychiatric disorders. For example, MICU3 has been shown to be involved in the development of Alzheimer's disease, which is a degenerative brain disorder that is characterized by the progressive loss of brain cells. Studies have shown that MICU3 is expressed in the brains of individuals with Alzheimer's disease and that its expression is associated with the severity of the disease.

In addition to its involvement in the development of Alzheimer's disease, MICU3 has also been shown to be involved in the regulation of other neurological disorders. For example, MICU3 has been shown to be involved in the development of Parkinson's disease, which is a neurodegenerative disorder that is characterized by the progressive loss of brain cells. Studies have shown that MICU3 is expressed in the brains of individuals with Parkinson's disease and that its expression is associated with the severity of the disease.

MICU3 has also been shown to be involved in the regulation of other psychiatric disorders, including schizophrenia. Studies have shown that MICU3 is expressed in the brains of individuals with schizophrenia and that its expression is associated with the severity of the disease.

In conclusion, MICU3 is a protein that is expressed in brain and spinal cord tissue and is involved in the development and maintenance of neural circuits. Its expression pattern in brain and spinal cord tissue makes it a potentially interesting drug target for a variety of neurological and psychiatric disorders, including Alzheimer's disease, Parkinson's disease, and schizophrenia. Further research is needed to fully understand the role of MICU3 in neural circuit development and maintenance.

Protein Name: Mitochondrial Calcium Uptake Family Member 3

Functions: May play a role in mitochondrial calcium uptake

More Common Targets

MID1 | MID1IP1 | MID1IP1-AS1 | MID2 | MIDEAS | MIDEAS-AS1 | MIDN | MIEF1 | MIEF2 | MIEN1 | MIER1 | MIER2 | MIER3 | MIF | MIF-AS1 | MIF4GD | MIGA1 | MIGA2 | MIIP | MILIP | MILR1 | MIMT1 | MINAR1 | MINAR2 | MINCR | MINDY1 | MINDY2 | MINDY2-DT | MINDY3 | MINDY4 | Minichromosome maintenance (MCM) 2-7 helicase complex | MINK1 | MINPP1 | MIOS | MIOX | MIP | MIPEP | MIPEPP3 | MIPOL1 | MIR1-1 | MIR1-1HG | MIR1-2 | MIR100 | MIR100HG | MIR101-1 | MIR101-2 | MIR10394 | MIR10396B | MIR10399 | MIR103A1 | MIR103A2 | MIR103B1 | MIR103B2 | MIR105-1 | MIR105-2 | MIR10527 | MIR106A | MIR106B | MIR107 | MIR10A | MIR10B | MIR11181 | MIR11400 | MIR11401 | MIR1178 | MIR1179 | MIR1180 | MIR1181 | MIR1182 | MIR1183 | MIR1184-1 | MIR1184-2 | MIR1184-3 | MIR1185-1 | MIR1185-2 | MIR1193 | MIR1197 | MIR1199 | MIR1200 | MIR1202 | MIR1203 | MIR1204 | MIR1205 | MIR1206 | MIR1207 | MIR1208 | MIR12129 | MIR12135 | MIR12136 | MIR122 | MIR1224 | MIR1225 | MIR1226 | MIR1227 | MIR1228 | MIR1229 | MIR1231 | MIR1233-1 | MIR1233-2 | MIR1234